Surrozen, Inc. (SRZN)

US — Healthcare Sector
Peers: BOLT  LRMR  KROS  KZR  PCSA  NEXI  EVLO  TPST  REPL  NVCT  LYRA  KRON  GOSS  ERYP  APM  UNCY  ARMP  CTMX  TIL  NLTX  SPRO  ASMB 

Automate Your Wheel Strategy on SRZN

With Tiblio's Option Bot, you can configure your own wheel strategy including SRZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SRZN
  • Rev/Share 2.9369
  • Book/Share 1.5639
  • PB 5.4286
  • Debt/Equity 1.4043
  • CurrentRatio 10.018
  • ROIC -0.2462

 

  • MktCap 72696304.0
  • FreeCF/Share -5.0185
  • PFCF -3.9928
  • PE -0.377
  • Debt/Assets 0.0694
  • DivYield 0
  • ROE 82.1765

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation SRZN H.C. Wainwright -- Buy -- $32 Jan. 30, 2025
Upgrade SRZN Guggenheim Neutral Buy -- $45 Jan. 3, 2025

News

Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround
SRZN
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Surrozen (SRZN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Read More
image for news Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround
Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases
SRZN
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in multiple severe and disabling eye diseases Announces an oversubscribed financing of $175 million in gross proceeds, which funds multiple ophthalmology programs through phase 1 safety, tolerability and efficacy studies Company discontinues clinical development of SZN-043 in severe alcohol associated hepatitis SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced that the company will focus its Wnt biology expertise …

Read More
image for news Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

About Surrozen, Inc. (SRZN)

  • IPO Date 2021-01-11
  • Website https://www.surrozen.com
  • Industry Biotechnology
  • CEO Mr. Craig C. Parker M.B.A.
  • Employees 40

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.